Logo image of GRX

GABELLI HEALTHCARE & WELL (GRX) Stock Overview

NYSE:GRX - US36246K1034

9.505 USD
+0.03 (+0.26%)
Last: 9/5/2025, 8:19:04 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to GRX. GRX was compared to 0 industry peers in the Unkown industry. GRX has a bad profitability rating. Also its financial health evaluation is rather negative. GRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GRX had negative earnings in the past year.
GRX had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: GRX reported negative net income in multiple years.
GRX had a positive operating cash flow in 4 of the past 5 years.
GRX Yearly Net Income VS EBIT VS OCF VS FCFGRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

1.2 Ratios

Industry RankSector Rank
ROA -0.13%
ROE -0.17%
ROIC N/A
ROA(3y)-6.34%
ROA(5y)0.14%
ROE(3y)-7.71%
ROE(5y)0.4%
ROIC(3y)N/A
ROIC(5y)N/A
GRX Yearly ROA, ROE, ROICGRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

GRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRX Yearly Profit, Operating, Gross MarginsGRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, GRX has about the same amount of shares outstanding.
Compared to 5 years ago, GRX has less shares outstanding
The debt/assets ratio for GRX is higher compared to a year ago.
GRX Yearly Shares OutstandingGRX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
GRX Yearly Total Debt VS Total AssetsGRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 1.97 indicates that GRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
GRX has a debt to FCF ratio of 4.15. This is a neutral value as GRX would need 4.15 years to pay back of all of its debts.
A Debt/Equity ratio of 0.32 indicates that GRX is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF 4.15
Altman-Z 1.97
ROIC/WACCN/A
WACCN/A
GRX Yearly LT Debt VS Equity VS FCFGRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 0.52 indicates that GRX may have some problems paying its short term obligations.
A Quick Ratio of 0.52 indicates that GRX may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.52
Quick Ratio 0.52
GRX Yearly Current Assets VS Current LiabilitesGRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

GRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -166.67%.
GRX shows a decrease in Revenue. In the last year, the revenue decreased by -4.05%.
Measured over the past years, GRX shows a decrease in Revenue. The Revenue has been decreasing by -0.67% on average per year.
EPS 1Y (TTM)-166.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%117.24%
Revenue 1Y (TTM)-4.05%
Revenue growth 3Y2.57%
Revenue growth 5Y-0.67%
Sales Q2Q%1.64%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRX Yearly Revenue VS EstimatesGRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRX Price Earnings VS Forward Price EarningsGRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 11.33
EV/EBITDA N/A
GRX Per share dataGRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 6.73%, GRX is a good candidate for dividend investing.
Compared to an average S&P500 Dividend Yield of 2.41, GRX pays a better dividend.
Industry RankSector Rank
Dividend Yield 6.73%

5.2 History

GRX has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of GRX decreased in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years2
GRX Yearly Dividends per shareGRX Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

The earnings of GRX are negative and hence is the payout ratio. GRX will probably not be able to sustain this dividend level.
DP-3231.03%
EPS Next 2YN/A
EPS Next 3YN/A
GRX Yearly Income VS Free CF VS DividendGRX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

More info and screens

GABELLI HEALTHCARE & WELL

NYSE:GRX (9/5/2025, 8:19:04 PM)

9.505

+0.03 (+0.26%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners35.05%
Inst Owner Change5.11%
Ins Owners1.81%
Ins Owner Change0%
Market Cap147.33M
Analysts0
Price TargetN/A
Short Float %0.03%
Short Ratio0.19
Dividend
Industry RankSector Rank
Dividend Yield 6.73%
Yearly Dividend0.59
Dividend Growth(5Y)N/A
DP-3231.03%
Div Incr Years0
Div Non Decr Years2
Ex-Date09-16 2025-09-16 (0.17)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 38.57
P/FCF 11.33
P/OCF 11.33
P/B 0.86
P/tB 0.86
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.84
FCFY8.82%
OCF(TTM)0.84
OCFY8.82%
SpS0.25
BVpS11.03
TBVpS11.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.13%
ROE -0.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 340.31%
ROA(3y)-6.34%
ROA(5y)0.14%
ROE(3y)-7.71%
ROE(5y)0.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF 4.15
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.52
Quick Ratio 0.52
Altman-Z 1.97
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-166.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%117.24%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-4.05%
Revenue growth 3Y2.57%
Revenue growth 5Y-0.67%
Sales Q2Q%1.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y96.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y96.67%
OCF growth 3YN/A
OCF growth 5YN/A